不同剂型紫杉醇治疗乳腺癌的疗效对比观察  

The clinical effect compare observation of different dosage forms of paclitaxel in the treatment of breast cancer

作　　者：胡苑婷 石坚如[1] 辛莉[1] HU Yuanting;SHI Jianru;XIN Li(Department of Pharmacy,Sun Yat-sen Memorial Hospital,Sun Yat-Sen University,Guangzhou 510120,China)

机构地区：[1]中山大学孙逸仙纪念医院药学部,广州市510120

出　　处：《临床合理用药杂志》2018年第25期29-30,共2页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的对比观察不同剂型紫杉醇治疗乳腺癌的临床效果。方法通过医院信息管理系统(HIS)和PIVAS系统调取2015年1月-2017年6月接受紫杉醇治疗的乳腺癌患者82例,收集患者的成本数据和临床疗效评价的结果,根据紫杉醇剂型分为3组,其中紫杉醇(预灌封)注射液(A组)28例,紫杉醇脂质体(B组)35例,紫杉醇白蛋白结合型(C组)19例。2个化疗周期后比较各组的临床疗效、不良反应和成本。结果 82例患者完成了至少2个周期化疗,总有效率为59.8(49/82),3组总有效率比较差异均无统计学意义(P>0.05)。A、B组不良反应均显著高于C组,差异均有统计学意义(P<0.05),A、B组不良反应比较差异均无统计学意义(P>0.05)。A组、B组、C组药品单价分别为134.58元、894.27元、5875.21元,化疗1个疗程平均成本分别为1076.64元、7154.36元、23369.23元。结论紫杉醇白蛋白结合型为基础的化疗方案治疗乳腺癌不良反应小、耐受性好,但紫杉醇白蛋白结合型昂贵的价格限制了其在临床的使用,临床应根据患者具体情况选择用药。Objective To compare the clinical effect of different dosage forms of paclitaxel in the treatment of breast cancer. Methods 82 patients with breast cancer who received paclitaxel from January 2015 to June 2017 were recruited through the Hospital Information Management System（ HIS） and the PIVAS system. Collect patient cost data and clinical efficacy evaluation results,According to the dosage form of paclitaxel,there were 3 groups,including 28 cases of paclitaxel（ prefilled） injection（ group A）,35 cases of paclitaxel liposome（ group B）,and 19 cases of paclitaxel albumin（ group C）. The clinical efficacy,adverse reactions and costs of each group were compared after 2 cycles of chemotherapy. Results Eighty-two patients completed at least 2 cycles of chemotherapy,the total effective rate was 59. 8（ 49/82）,and the total effective rate of the three groups was not statistically significant（ P 〉0. 05）. The adverse reactions in group A and group B were significantly higher than those in group C（ P〈 0. 05）. There was no significant difference in the adverse reactions between group A and group B（ P 〉0. 05）. The unit price of drugs in group A,group B and group C was 134. 58 yuan,894. 27 yuan and 5 875. 21 yuan respectively. The average cost of chemotherapy for one course was 1 076. 64 yuan,7 154. 36 yuan and 23 369. 23 yuan respectively. Conclusion The paclitaxel-binding-based chemotherapy regimen is effective in treating breast cancer,and the adverse reactions are small and well tolerated. However,the expensive price of paclitaxel albumin binding limits its clinical use,and the clinical situation should be based on the patient＇s specific situation.

关 键 词：乳腺癌 紫杉醇 紫杉醇脂质体 紫杉醇白蛋白结合型 

分 类 号：R737.9[医药卫生—肿瘤]